Drugmaker Tranzyme (TZYM) +11.7% premarket on news it will explore a possible sale of the...
Drugmaker Tranzyme (TZYM) +11.7% premarket on news it will explore a possible sale of the company, less than two years after it went public. Two mid-stage trials of its development drug for stomach paralysis recently were dropped due to lack of efficacy.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Sep 13, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs